Herpes simplex virus immunoglobulin 2 types of the person

General characteristics. Structure:

Active ingredients - specific antibodies to a herpes simplex virus 2 types;

the stabilizer – glycine (glycine, the aminoacetic acid).

Main properties: drug is immunological the active protein fraction allocated from the blood plasma of the person cleared and concentrated by a fractionation method alcohol, which passed a stage of a virus inactivation solvent-detergentnym by method. Protein content in 1,0 ml of drug from 0,09 g to 0,11 g. Transparent or slightly opalescent, colourless or yellowish liquid. In the course of storage emergence of an insignificant deposit which disappears when stirring is possible. Drug contains antibodies to a herpes simplex virus 2 types. Drug does not contain preservative and antibiotics, in raw materials there are no antibodies to VICh-1, VICh-2, to a virus of hepatitis C and a surface antigen of a virus of hepatitis In (HBsAg).

Pharmacological properties:

The operating basis of drug are antibodies, 2 types, in particular immunoglobulin G, specific to a herpes simplex virus. Specific activity of drug is caused by virus neutralizing action of antibodies. Besides, immunoglobulin G, causes immunomodulatory effect, influencing different links of immune system of the person, and increases nonspecific resistance of an organism.

Indications to use:

Drug is used for the purpose of treatment various on clinical displays of the diseases caused by a herpes simplex virus 2 types:

- primary and recurrent urogenital infection at men and women;

- a genital herpes infection at pregnant women and the related obstetric pathology.

Route of administration and doses:

Immunoglobulin is entered intramusculary.

Primary and recurrent genital herpes infection – intramusculary 1,5 ml (1 dose) once in three days. A course of treatment – 7 injections, and also locally – processing of bubbly herpetic rashes.

Herpes genital infection at pregnant women. The first course of treatment is begun after 12 weeks of pregnancy. The drug is administered intramusculary by 1,5 ml (1 dose) of 1 times in three days, 6 injections. The second year is begun after 36 weeks of pregnancy. The drug is administered intramusculary by 1,5 ml (1 dose) of 1 times in three days, 6 injections then immunoglobulin is entered intravaginalno the syringe without needle within 5 days after preliminary washing of a vagina normal saline solution.

Features of use:

Administration of drug is intravenously forbidden!

Side effects:

Reactions to administration of immunoglobulin, as a rule, are absent. In rare instances local reactions in the form of a hyperemia and temperature increase to ^{37,5 0C} within the first days can develop. At certain people with the changed reactivity allergic reactions of various type, and in exclusively exceptional cases - an acute anaphylaxis can develop. In this regard the persons who received drug have to be under medical observation within 30 minutes.

Interaction with other medicines:

The combination with other antiherpetic drugs (an acyclovir, zovirax, герпевир) just before use of immunoglobulin or at the same time within 5 – 10 days on 0,2 g of 5 times a day is possible.

Contraindications:

Administration of immunoglobulin is contraindicated to the persons having heavy allergic reactions to introduction of proteinaceous blood preparations of the person in the anamnesis. Or having a serious allergic illness in the anamnesis, in day of administration of immunoglobulin and in the next 3 days antihistaminic drugs are recommended to the patients having allergic diseases. To the persons suffering from immune general diseases (diseases of blood, connecting fabric, nephrite, etc.), it is necessary to enter immunoglobulin against the background of the corresponding therapy.

Overdose:

It was not studied.

Storage conditions:

In the dry, protected from light place at a temperature from 2 °C to 8 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

In ampoules on 1,5 ml (1 dose) and 3,0 ml (2 doses) on 5 or 10 ampoules in a box with a corrugated insert or with a polymeric insert from a film polyvinyl chloride for placement and fixing of ampoules.